Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells

Transplantation

Volumn 91, Issue 5, 2011, Pages 494-500

  D'Orsogna, Lloyd J A ^a   Roelen, Dave L ^a   Van Der Meer Prins, Ellen M W ^a   Van Der Pol, Pieter ^a   Franke Van Dijk, Marry E ^a   Eikmans, Michael ^a   Anholts, Jacqy ^a   Rossjohn, Jamie ^b   McCluskey, James ^c   Mulder, Arend ^a   Van Kooten, Cees ^a   Doxiadis, Ilias I N ^a   Claas, Frans H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alloreactivity; EBV; Heterologous immunity; Memory T cells; Tissue specificity

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3A; HLA B ANTIGEN; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXICITY; DILUTION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY TUBULE CELL; LYMPHOCYTE CLONE; LYSIS; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; TISSUE SPECIFICITY; UMBILICAL VEIN ENDOTHELIAL CELL;

ATP-BINDING CASSETTE TRANSPORTERS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS REACTIONS; ENDOTHELIUM, VASCULAR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HLA-B ANTIGENS; HUMANS; KIDNEY TUBULES, PROXIMAL; ORGAN SPECIFICITY; PEPTIDES;

EID: 79952196407     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318207944c     Document Type: Article

References (47)

1. Adams A, Williams M, Jones T, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887.
2. Brook M, Wood K, Jones N. The impact of memory T-cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1.
3. Selin L, Brehm M. Frontiers in nephrology: Heterologous immunity, T cell cross reactivity and alloreactivity. J Am Soc Nephrol 2007; 18: 2268.
4. Welsh R, Selin L. No one is naïve: The significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2: 417.
5. Burrows S, Khanna R, Silins S, et al. The influence of antiviral T-cell responses on the alloreactive repertoire. Immunol Today 1999; 20: 203.
6. Yang H, Welsh R. Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol 1986; 136: 1186.
7. Wang T, Chen L, Ahmed E, et al. Prevention of allograft tolerance by bacterial infection with listeria monocytogenes. J Immunol 2008; 180: 5991.
8. Welsh R, Markees T, Woda B, et al. Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti- CD154 antibody. J Virol 2000; 74: 2210.
9. Webb S, Sprent J. T-cells with multiple specificities. Int Rev Immunol 1986; 1: 151.
10. Wang T, Ahmed E, Chen L, et al. Infection with the intracellular bacterium, listeria monocytogenes, overrides established tolerance in a mouse cardiac allograft model. Am J Transplant 2010; 10: 1524.
11. Amir A, D'Orsogna L, Roelen D, et al. Allo-HLA reactivity of viral specific memory T-cells is common. Blood 2010; 115: 3146.
12. Macdonald W, Chen Z, Gras S, et al. T cell recognition via molecular mimicry. Immunity 2009; 31: 897.
13. Archbold J, Macdonald W, Miles J, et al. Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is the result of highly focused, peptide-dependent structural mimicry. J Biol Chem 2006; 281: 34324.
14. Gaston J, Rickinson A, Epstein M. Crossreactivity of self-HLArestricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo- HLA determinants. J Exp Med 1983; 158: 1804.
15. Burrows S, Khanna R, Burrows J, et al. An alloresponse in humans is dominated by cytotoxic T-lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: Implications for graft-vs-host disease. J Exp Med 1994; 179: 1155.
16. D'Orsogna L, Amir A, Zoet Y, et al. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire. Tissue Antigens 2009; 74: 290.
17. Maruya E, Takemoto S, Terasaki P. HLA matching: Identification of permissible HLA mismatches. Clin Transplant 1993; 9: 511.
18. Woltman A, De Haij S, Boonstra J, et al. Interleukin-17 and CD40- ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000; 11: 2044.
19. van Kooten C, Gerritsma J, Paape M, et al. Possible role for the CD40- CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997; 51: 711.
20. Stobbe I, van der Meer-Prins E, Smits J, et al. In vitro reactivity of allo-specific cytotoxic T lymphocytes does not explain the taboo phenomenon. Transplant Immunol 1999; 7: 215.
21. Miltenburg A, Meijer-Paape M, Daha M, et al. Donor-specific lysis of human proximal tubular epithelial cells by renal allograft-infiltrating lymphocytes. Transplantation 1989; 48: 296.
22. Van Der Woude F, Daha M, Miltenburg A, et al. Renal allograft-infiltrated lymphocytes and proximal tubular cells: Further analysis of donor-specific lysis. Hum Immunol 1990; 28: 186.
23. Maciag T, Hoover G, Stemerman M, et al. Serial propagation of human endothelial cells in vitro. J Cell Biol 1981; 91: 420.
24. Gordon P, Sussman I, Hatcher V. Long-term culture of human endothelial cells. In Vitro 1983; 19: 661.
25. Lewis LJ, Hoak JC, Maca RD, et al. Replication of human endothelial cells in culture. Science 1973; 181: 453.
26. Jin Y, Jindra P, Gong K, et al. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79; S19.
27. Seder R, Darrah P, Roederer M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol 2008; 8: 247.
28. Venturi V, Price D, Douek D, et al. The molecular basis for public T-cell responses? Nat Rev Immunol 2008; 8: 231.
29. Byrne J, Butler J, Cooper M. Differential activation requirements for virgin and memory T cells. J Immunol 1988; 141: 3249.
30. Hamann D, Baars P, Rep M, et al. Phenotypic and Functional Separation of memory and effector human CD8- T cells. J Exp Med 1997; 186: 1407.
31. Heath W, Sherman L. Cell-type-specific recognition of allogeneic cells by alloreactive cytotoxic T cells: A consequence of peptide-dependent allorecognition. Eur J Immunol 1991; 21: 153.
32. Peh C, Burrows S, Barnden M, et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998; 8: 531.
33. Williams A, Peh C, Purcell A, et al. Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity 2002: 16; 509.
34. Johnson D, Mook-Kanamori B. Dependence of elevated human leukocyte antigen class I molecule expression on increased heavy chain, light chain (-2-Microglobulin), transporter associated with antigen processing, tapasin and peptide. J Biol Chem 2000: 275; 16643.
35. Schild H, Rotzschke O, Kalbacher H, et al. Limit of T cell tolerance to self-proteins by peptide presentation. Science 1990; 247: 1587.
36. Minami M, Kawasaki H, Taira S, et al. Alloantigen presentation by B-cells; two types of alloreactive T cell hybridomas, B cell reactive and B cell-nonreactive. J Immunol 1985; 135: 111.
37. Molina I, Huber B. The expression of tissue-specific self-peptide is required for allorecognition. J Immunol 1990; 144: 2082.
38. Marrack P, Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature 1988; 332: 840.
39. Deckers J, Daha M, Van Der Kooij S, et al. Epithelial and endothelial-cell specificity of renal graft infiltrating T cells. Clin Transplant 1998; 12: 285.
40. Yard B, Claas F, Paape M, et al. Recognition of a tissue-specific polymorphism by graft infiltrating T-cell clones isolated from a renal allograft with acute rejection. Nephrol Dial Transplant 1994; 9: 805.
41. Van Der Woude F, Deckers J, Mallat M, et al. Tissue antigens in tubulointerstitial and vascular rejection. Kidney Int Suppl 1995; 52: S11.
42. Boonstra J, Deckers J, Laterveer J, et al. Pancreas and kidney allograftinfiltrating cells in simultaneous pancreas-kidney transplantation. Transplantation 1997; 63: 1470.
43. Deckers J, Boonstra J, Van Der Kooij S, et al. Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection. Transplantation 1997; 64: 178.
44. Bestard O, Nickel P, Cuzado J, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19: 1419.
45. Burrows S, Khanna R, Moss D. Direct alloreactivity by human T lymphocytes can be inhibited by altered peptide ligand antagonism. Blood 1999; 93: 1020.
46. Borst J, De Vries E, Spits H, et al. Complexity of T-cell receptor recognition sites for defined alloantigens. J Immunol 1987; 139: 1952.
47. Spits H, Paliard X, Engelhard V, et al. Cytotoxic activity and lymphokine production of T cell receptor (TCR)-alpha beta- and TCRgamma delta- cytotoxic T lymphocyte (CTL) clones recognizing HLA-A2 and HLA-A2 mutants. Recognition of TCR-gamma delta- CTL clones is affected by mutations at positions 152 and 156. J Immunol 1990; 144: 4156.